This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Maribavir for Prevention of CMV After Stem Cell Transplants

This study has been completed.
Information provided by (Responsible Party):
Shire Identifier:
First received: September 13, 2005
Last updated: March 25, 2015
Last verified: March 2014
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.

Condition Intervention Phase
Cytomegalovirus Infection Drug: Maribavir Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Clinical safety as measured by the recording of treatment emergent adverse events [ Time Frame: 13 weeks ]

Secondary Outcome Measures:
  • Incidence of CMV disease [ Time Frame: 13 weeks ]
  • Incidence of CMV infection [ Time Frame: 13 weeks ]

Enrollment: 111
Study Start Date: October 2004
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Experimental: Maribavir (100 mg twice daily) Drug: Maribavir
Experimental: Maribavir (400 mg twice daily) Drug: Maribavir
Experimental: Maribavir (400 mg once daily) Drug: Maribavir


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Allogeneic stem cell transplant recipient
  • Recipient CMV seropositive
  • Have transplant engraftment
  • Able to swallow tablets

Exclusion Criteria:

  • CMV organ disease
  • HIV infection
  • Use of other anti-CMV therapy post-transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00223925

United States, California
City of Hope Medical Center
Duarte, California, United States
UCLA Medical Center
Los Angeles, California, United States
United States, Illinois
Loyola University
Maywood, Illinois, United States
United States, Massachusetts
Tufts-New England Medical Center
Boston, Massachusetts, United States
United States, Michigan
Wayne State Medical Center
Detroit, Michigan, United States
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
United States, North Carolina
Duke Medical Center
Durham, North Carolina, United States
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
United States, Utah
University of Utah
Salt Lake City, Utah, United States
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Shire Identifier: NCT00223925     History of Changes
Other Study ID Numbers: 1263-200
Study First Received: September 13, 2005
Last Updated: March 25, 2015

Keywords provided by Shire:
Stem cell transplantation
Allogeneic transplantation

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases processed this record on September 21, 2017